Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Insite Vision Inc. -- Ignore unavailable to you. Want to Upgrade?

To: DOLLAR BILL who wrote (965)	8/10/1999 4:07:00 PM
From: bob zagorin	Respond to of 1060

InSite Vision Licenses AquaSite to SSP Co., Ltd -- Introducing Unique Product to Large Japanese Market ALAMEDA, Calif.--(BW HealthWire)--Aug. 10, 1999--InSite Vision Incorporated (AMEX: ISV) announced today that it has signed an exclusive licensing agreement granting the Japanese rights to AquaSite(R) its proprietary, sustained release dry eye treatment, to SSP Co., Ltd. of Tokyo, Japan. SSP is a leading Japanese pharmaceutical company with 310 products currently on the market, including over-the-counter and prescription drugs and other health care products. SSP expects to begin producing and marketing AquaSite by early 2000. This agreement represents a continuation of an aggressive licensing and partnering program begun by InSite earlier this year, which already has resulted in a number of potentially profitable programs. "This agreement with SSP represents a significant expansion of our marketing efforts in Asia. Earlier this year, we signed manufacturing and distribution agreements with two Korean companies," said Dr. S. Kumar Chandrasekaran, Chairman and CEO of InSite. "In many ways, Japan is a key market for our special product area of genetically based glaucoma diagnostics and treatment. Glaucoma is a major cause of blindness in Japan, and an estimated 75% of Japanese patients do not respond to the traditional diagnostic test, which measures intraocular pressure. InSite's genetic-based ISV-900 diagnostic product does not rely on eye pressure measurements and, therefore, should improve dramatically the early detection of glaucoma in the large Japanese market," Dr. Chandrasekaran said. InSite Vision is an ophthalmic product development company focused on genetic research for the diagnosis and prognosis of glaucoma and a novel glaucoma treatment using its proprietary DuraSite technology. This press release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision. Such statements entail a number of risks and uncertainties involving the results of preclinical and clinical studies and determinations by the U.S. Food and Drug Administration, as well as the Risk Factors listed from time to time in InSite's SEC filings including, but not limited to, its Form 10-Q for the quarter ended March 31, 1999. CONTACT: InSite Vision Sandra Heine, 510/865-8800 or Investor Contacts: Core Communications Group, Inc. SF, Robert Ferri, 415/331-7003 rferri@nextwavestocks.com or NY, Joshua Z. Levine, 516/487-8322 jzlevine@nextwavestocks.com .